UCB agreed to buy Neurona for up to $1.2 billion, aiming to expand beyond its small-molecule epilepsy portfolio into seizure cell therapy. UCB said the deal helps diversify its pipeline with a one-off therapy in early testing for a hard-to-treat form of epilepsy. The acquisition reflects a broader strategy among established biopharmas to add modality breadth—particularly cell-based approaches—where conventional drugs face limits in durable disease control. It also sets up Neurona’s assets to benefit from UCB’s development and commercialization infrastructure. For investors and partners, the structure “up to” suggests the price will likely depend on clinical or regulatory milestones, while integrating Neurona’s early-stage program into UCB’s longer-term pipeline building.